Product Name:MOTs-C
Cas No:1627580-64-6
Molar Mass:2174.6
Chemical Formula:C101H152N28O22S2
Synonyms:UNII-A5CV6JFB78
Storage:Store at -20°C
Sequence:MRWQEMGYIFYPRKLR
Target Indicators:AMPK
Application:MOTS-c, or mitochondrial open reading frame of the 12S rRNA-c, is a small peptide encoded within the mitochondrial genome. It plays a crucial role in regulating cellular metabolism and energy production by interacting with various cellular pathways. In pharmaceutical chemistry, MOTS-c is studied for its potential therapeutic applications in metabolic disorders, such as obesity, insulin resistance, and type 2 diabetes. It exerts its effects by promoting mitochondrial biogenesis, improving insulin sensitivity, and enhancing glucose metabolism. Additionally, MOTS-c has shown promise in combating age-related decline in mitochondrial function and promoting longevity in preclinical studies. Its mechanism of action in modulating mitochondrial function and cellular metabolism highlights its potential as a novel therapeutic target for addressing metabolic diseases and promoting overall health and well-being.
Current Research:
MOTS-c, short for mitochondrial open reading frame of the twelve S-c, is a recently discovered mitochondrial-derived peptide (MDP) with significant implications for cellular metabolism and cytoprotection. Mitochondria, crucial organelles responsible for energy production and metabolism, are sensitive to various stressors, including intrinsic factors like mutations in mitochondrial DNA (mtDNA) and extrinsic agents like toxins and pathogens. Chemicals and stressors can alter mitochondrial function, leading to aging, neurological disorders, diabetes, and cancer. Mitochondrial dysfunction is also associated with age-related metabolic deterioration and the decline of physical capabilities.
Research on MOTS-c has shed light on its role as a nuclear regulatory peptide and its potential therapeutic applications in aging and age-related disorders. MOTS-c modulates cellular metabolism and provides cytoprotection, challenging previous notions of mitochondrial activity. Studies suggest that MOTS-c levels decrease with age, possibly due to mitochondrial genetic changes and the progressive degradation of mtDNA. This decline in MOTS-c levels may contribute to age-related metabolic dysfunction and the development of diseases like diabetes and metabolic syndrome.
Interestingly, MOTS-c shares metabolic pathways with age-modifiers like NAD+, a coenzyme involved in redox activities that declines with age. Increasing NAD+ levels has been shown to improve age-related disorders, as it activates sirtuins, proteins that regulate aging and age-related diseases. MOTS-c elevates intracellular NAD+ levels and inhibits the folate/methionine cycle, leading to reduced methionine metabolism. Methionine restriction, similar to the effects induced by MOTS-c, has been associated with lifespan extension and reduced age-related illnesses in rodents.
The potential therapeutic value of MOTS-c in treating age-related diseases highlights the importance of further clinical research into its response to age-related treatments. By raising awareness of MOTS-c’s therapeutic potential, this review aims to stimulate more research into the mechanisms and applications of this novel class of peptides. Ultimately, understanding the role of MOTS-c in cellular metabolism and aging could lead to the development of targeted interventions for age-related morbidities, offering new avenues for improving healthspan and longevity.
